Tim Jedamzik, Aleksander Kosmala, Stefan Kircher, Marieke Heinrich, Wiebke Schlötelburg, Andreas K Buck, Alexander Meining, Rudolf A Werner, Alexander Weich, Kerstin Michalski
{"title":"Prognostic impact of discordant lesions on [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT compared to histological FAP expression in neuroendocrine neoplasms.","authors":"Tim Jedamzik, Aleksander Kosmala, Stefan Kircher, Marieke Heinrich, Wiebke Schlötelburg, Andreas K Buck, Alexander Meining, Rudolf A Werner, Alexander Weich, Kerstin Michalski","doi":"10.3389/fnume.2026.1777541","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>On dual-tracer positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) and fibroblast activation protein inhibitor ([⁶⁸Ga]Ga-FAPI-04), discordant lesions (FDG+/FAPI-) in aggressive neuroendocrine neoplasms (NENs) are linked to shorter progression-free survival (PFS). This study evaluated the prognostic value of such lesions in comparison to histological fibroblast activation protein (FAP) expression from a clinically obtained biopsy and their impact on PFS.</p><p><strong>Methods: </strong>23 patients with aggressive NENs underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT as well as biopsy within a short period of time. PET parameters [standardized uptake values (SUV): SUVmax, SUVmean, SUVpeak] were measured, as were tumor volume (TV), and total lesion uptake (TLU = TV × SUVmean). FDG+/FAPI- lesions were identified. FAP expression was assessed immunohistochemically using the immunoreactive score (IRS-FAP). Correlations between PET metrics, IRS-FAP, and FDG+/FAPI- lesions were analyzed. Cox regression and log-rank test were used to evaluate associations with PFS.</p><p><strong>Results: </strong>IRS-FAP correlated significantly with TV ([¹⁸F]FDG: p=0.0165; [⁶⁸Ga]Ga-FAPI-04: <i>p</i> = 0.0181) and TLU ([¹⁸F]FDG: <i>p</i> = 0.0170; [⁶⁸Ga]Ga-FAPI-04: <i>p</i> = 0.0253). There was no significant correlation for IRS-FAP with SUV parameters. FDG+/FAPI- lesions were found in 9/23 patients and associated with significantly shorter PFS (4 vs. 10 months, HR: 3.383, <i>p</i> = 0.0015). [¹⁸F]FDG-TV and [¹⁸F]FDG-TLU correlated with PFS, but IRS-FAP showed no significant association with either PFS or FDG+/FAPI- lesions.</p><p><strong>Conclusions: </strong>FAP expression on immunohistochemistry obtained from a single biopsy site does not predict discordant PET/CT findings. In contrast, the presence of FDG+/FAPI- lesions is a strong prognostic factor for reduced PFS. Thus, dual-tracer PET/CT may offer superior risk stratification compared to single-lesion histological FAP assessment in aggressive NENs.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":"6 ","pages":"1777541"},"PeriodicalIF":1.4000,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13106593/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2026.1777541","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: On dual-tracer positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) and fibroblast activation protein inhibitor ([⁶⁸Ga]Ga-FAPI-04), discordant lesions (FDG+/FAPI-) in aggressive neuroendocrine neoplasms (NENs) are linked to shorter progression-free survival (PFS). This study evaluated the prognostic value of such lesions in comparison to histological fibroblast activation protein (FAP) expression from a clinically obtained biopsy and their impact on PFS.
Methods: 23 patients with aggressive NENs underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT as well as biopsy within a short period of time. PET parameters [standardized uptake values (SUV): SUVmax, SUVmean, SUVpeak] were measured, as were tumor volume (TV), and total lesion uptake (TLU = TV × SUVmean). FDG+/FAPI- lesions were identified. FAP expression was assessed immunohistochemically using the immunoreactive score (IRS-FAP). Correlations between PET metrics, IRS-FAP, and FDG+/FAPI- lesions were analyzed. Cox regression and log-rank test were used to evaluate associations with PFS.
Results: IRS-FAP correlated significantly with TV ([¹⁸F]FDG: p=0.0165; [⁶⁸Ga]Ga-FAPI-04: p = 0.0181) and TLU ([¹⁸F]FDG: p = 0.0170; [⁶⁸Ga]Ga-FAPI-04: p = 0.0253). There was no significant correlation for IRS-FAP with SUV parameters. FDG+/FAPI- lesions were found in 9/23 patients and associated with significantly shorter PFS (4 vs. 10 months, HR: 3.383, p = 0.0015). [¹⁸F]FDG-TV and [¹⁸F]FDG-TLU correlated with PFS, but IRS-FAP showed no significant association with either PFS or FDG+/FAPI- lesions.
Conclusions: FAP expression on immunohistochemistry obtained from a single biopsy site does not predict discordant PET/CT findings. In contrast, the presence of FDG+/FAPI- lesions is a strong prognostic factor for reduced PFS. Thus, dual-tracer PET/CT may offer superior risk stratification compared to single-lesion histological FAP assessment in aggressive NENs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
